Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Anti–Tumor Necrosis Factor Therapy in Crohn's Disease: More Information and More Questions About the Long Term

(2010) Charles N. Bernstein   Clinical Gastroenterology and Hepatology

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

(2010) Gary R. Lichtenstein et al.   Clinical Gastroenterology and Hepatology

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

(2008) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET